ArticleRheumatology advances in practice2026
Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: While RA and menopausal hormone treatment (MHT) are known to increase the risk of venous thromboembolism (VTE), how MHT influences VTE incidence within the RA population has not been well-characterised. This study aimed to evaluate whether MHT is associated with an increased risk of VTE in peri- and postmenopausal women with RA. Methods: We conducted a retrospective, matched cohort study using UK primary care data from the Clinical Practice Research Datalink (CPRD) Aurum, linked to secondary care, from 2001 to 2021. Women ages 40-79 years with RA initiating MHT were matched to women with RA not initiating MHT. VTE incidence rates were calculated and Cox proportional hazards models adjusted for risk factors estimated the MHT-associated VTE risk. Results: A total of 2187 women with RA initiating MHT were matched to 8205 unexposed controls. VTE incidence was higher among MHT users [6.49 (95% CI 4.28, 9.44) per 1000 person-years Conclusion: MHT use in peri- and postmenopausal women with RA is associated with a 2-fold increased risk of VTE, particularly DVT, relative to unexposed controls. Individualised risk assessment and monitoring are advised, taking into account the patient's clinical context. Clinicians should balance MHT benefits against thrombotic risks and consider alternatives or preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.